Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter




Read in Swedish

Probi completes first production batches of dairy-free BLIS K12

14:00 / 31 March 2022 Probi Press release

Probi[®] has completed the first commercial production batches of a dairy-free Streptococcus salivarius BLIS K12 at its US manufacturing site. The new BLIS[®] strains will shortly be offered to customers around the world.

Probi entered a strategic partnership with New Zealand based Blis Technologies Ltd. as part of a long-term strategic collaboration in July, 2021. As part of this partnership, Probi[®] and Blis signed a licensing and distribution agreement. Probi is now manufacturing BLIS[®] strains at its recently upgraded fermentation facility in Redmond, WA and will shortly be offering these new strains to Probi's customers around the world. In addition, the two companies are continuing to collaborate on additional research and development.

Streptococcus salivarius BLIS K12 is part of a portfolio of clinically documented bacterial strains for supporting our natural immune defense and preventing infections of the mouth and throat. The BLIS strains also contribute to a healthy set of teeth and gums. Blis Technologies' clinically documented strains have a successful history of use in New Zealand, Australia and Asia, as well as in Europe and in North America.

Steve Preston, Probi's Head of Fermentation stated: "The technology transfer of BLIS strains to Probi has gone smoothly and we have been able to make very rapid progress due to our sizable investments in fermentation technology and upgrades to our analytical capability. Furthermore, as part of our high throughput screening program for culture media optimization, we have been able to completely eliminate the need for dairy (milk) products in the formulation. We believe this is very helpful for customers seeking to produce allergen free probiotic products."

For further information, please contact:

Tom Rönnlund, CEO, Probi[®]: Phone: +46 46 286 89 40, E-mail:
Henrik Lundkvist, CFO, Probi[®]: Phone: +46 46 286 89 41, E-mail:


Probi[®] is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. The company is an expert in managing stable, live bacteria from research through every stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Since the company was founded in 1991 at Lund University in Sweden, Probi has expanded its operations to more than 40 markets and holds more than 400 patents worldwide. Probi had sales of SEK 658 m in 2021. Probi's shares are listed on Nasdaq Stockholm, Mid-cap. and there were around 3,800 shareholders on December 31, 2021.

Probi[®] is a registered trademark of Probi AB. Read more at


Blis Technologies develops and manufactures advanced probiotic strains outside the field of gastric health. Combining innovation with evidence-based research and the highest quality production controls, enables the delivery of probiotic solutions for specific health areas including ears, nose, throat, halitosis (bad breath), immune health, teeth and gums and skin care. Blis Technologies sells products under both its own brand and through licensing. BLIS[®] products are sold throughout New Zealand and Australia, Asia, Europe and the USA. The company is listed on NZX. More information about Blis Technologies Ltd can be found at

Show as PDF

Show original from Cision


This information was distributed by Cision